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Objective: to evaluate the association between Apolipoprotein AI (ApoAI), Apolipoprotein B100 (ApoB) and the presence
of lower limb atherosclerotic occlusive disease.
Materials and methods: serum lipids, lipoprotein fractions, ApoAI, ApoB and Lp(a) were measured in 52 patients
(28 diabetics and 24 non-diabetics) with lower limb occlusive disease. They were evaluated according to patients' glucose
and compared with those in 75 healthy controls.
Results: there was a significant decrease in HDL-cholesterol and ApoAI serum levels (p 0.000001) and an increase in
Lp(a) (p 0.000001) in patients as compared to controls. No difference was observed in total cholesterol, non HDL-
cholesterol or triglycerides. Multiple regression analysis revealed a significant association between low ApoAI (or HDL)
levels and the disease as well as between high Lp(a) levels and the disease.
ApoAI (p 0.0003), HDL-cholesterol (p 0.00005) and total cholesterol (p 0.01) levels were significantly lower in
diabetic patients compared to non-diabetic patients. Lp(a) levels did not correlate with fasting glucose concentration.
Multiple regression analysis revealed a significant association between low ApoAI (or HDL) levels and diabetes.
Conclusion: decreased ApoAI appears to be a main component of the dyslipidaemic serum profile observed in patients with
atherosclerotic occlusive disease of the lower extremities. Increased Lp(a) levels is an independent risk factor. Decreased
HDL-cholesterol is also involved in the dyslipidaemic profile.
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disease; Peripheral vascular disease (PVD); Diabetes.
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Several studies have presented a correlation between
lipoprotein parameters and peripheral atherosclerosis.
Plasma total cholesterol has not consistently been
associated with this disorder.1±5 More frequently the
disease was associated with an increase in triglycer-
ides, that is usually lost on multivariate analysis
after adjustment for total cholesterol.3,5,6 A reduction
in HDL-cholesterol plasma levels has also been
observed3,5,6 while recent studies have considered
the role of lipoprotein (a) [Lp(a)].4,7±9 On the contrary
the association of the disease with apolipoproteins
has not been investigated extensively. ApolipoproteinPlease address all correspondence to: A. Dionyssiou-Asteriou,
Deptartment of Biological Chemistry, University of Athens Medical
School, 75 M. Asias str., GR-115 27 Athens, Greece.
1078±5884/02/020161  05 $35.00/0 # 2002 Elsevier Science Ltd. AAI (ApoAI) is the major protein found in HDL and
apolipoprotein B100 (ApoB) the major protein
moiety of all lipoproteins other than HDL; since both
are not subject to exchange among lipoproteins, their
plasma levels are better correlated with lipoprotein
concentration than the cholesterol content of lipo-
protein particles. In this sense, it has been suggested
that the plasma concentrations of ApoAI and ApoB
are better discriminants of patients with athero-
sclerosis than are traditional lipid measures.8,10±12
Furthermore apolipoprotein concentrations are not
influenced by a meal and might be more useful
measures when the fasting status of a patient is in
question.13
The purpose of the present study was to evaluate
whether the association between ApoAI, ApoB and
Lp(a) and the presence of lower limb atherosclerotic
occlusive disease provide additional information over
that given by traditional lipid measures.ll rights reserved.
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Subjects
Fifty-two patients (42 males and 10 females) attending
a vascular clinic, with symptoms of atherosclerotic
occlusive disease of the lower extremities were
included in the present study. Thirty-six of the studied
patients suffered from pain at rest and 16 had symp-
toms such as claudication according to the Edinburgh
Claudication Questionnaire14 (Table 1). All the above
patients also had an ankle-brachial pressure index
0.8. Individuals with renal or hepatic dysfunction
and those taking corticosteroids or lipid modifying
medication were excluded from the study. Thirty-
three of the patients underwent retrograde transcuta-
neous angiography15 and 19 were subjected to
intravenous digital subtraction angiography.3 No one
of the patients had undergone previous vascular sur-
gery. The 52 patients were separated in diabetics (23
males and 5 females) and non-diabetics (18 males and
6 females) on the basis of a history of documented
fasting hyperglycaemia. The diabetic patients were
under antidiabetic (glibenclamide) or insulin. The
therapeutic treatment of patients included the admin-
istration of buflomedil and pentoxyphiline plus
enalapril, captopril or diltiazem for those with
hypertension.
A group of 75 healthy non obese individuals (60
males and 15 females) with no family history of car-
diovascular or peripheral artery disease, who had vis-
ited a major Health Centre in Athens for an annual
check-up examination, served as controls (Table 1).
They were seen clinically and were assessed by ultra-
sounds in order to exclude stenosis in the peripheral
vessels of the lower extremities using a Doppler/
Triplex ATL4PLUS. Only subjects without stenosisTable 1. Similarities and differences between cases and controls.
Cases
(n 52)
Controls
(n 75)
Age (years) [mean SD (range)] 69 10 (50±84) 64 9 (50±75)
BMI [median (range)] 25.5 (23±31) 25 (22±29)y
Sex
Males (%) 42 (81) 60 (80)
Females (%) 10 (19) 15 (20)
Smokers (%) 36 (69) 55 (73)
Diabetes (%) 28 (54) 3 (4)
Hypertension (%) 24 (46) 5 (6)
History CVD (%) 22 (42) 0 (0)
Social class Middle class Middle class
Lower limb occlusive disease
Moderate claudication (%) 16 (31) 0 (0)
Rest pain (%) 36 (69) 0 (0)
 n 51.
y n 70.
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lowering therapy.
Lipoprotein analysis
Blood samples were taken after overnight fasting
(12 h). The serum was separated by centrifugation at
1500 g for 15 min. HDL-cholesterol was determined
in the supernatant fluid obtained from whole serum
after precipitation of VLDL and LDL by magnesium
chloride and dextran sulphate. Serum cholesterol and
triglycerides, as well as HDL-cholesterol, were mea-
sured in a COBAS MIRA PLUS (ROCHE) autoanaly-
zer. The sum of the cholesterol in ApoB-lipoproteins
was designated as non HDL-cholesterol and was cal-
culated as total cholesterol minus HDL-cholesterol.16
ApoAI and ApoB were quantified by immunonephe-
lometry with reagents supplied by Berring-Werke
A.G. (Germany). Serum glucose was determined
with a Beckman glucose analyser (Palo Alto, CA,
U.S.A.), using a glucose oxidase method. Serum
Apo(a) concentration was measured with a two-site
immunoradiometric assay (2-site IRMA) developed
by Pharmacia Diagnostics AB (Uppsala, Sweden) as
described previously.17 The within-assay coefficient
of variation was 5% (n 10). One U/L Apo(a) corre-
sponds approximately to 0.1 mg/dl of Lp(a) protein.
All samples were assayed in duplicate.
Statistical analysis
The data were analysed by using the STATISTIKA
(version 5) programs. The comparison between mean
values of the examined parameters was carried out by
the Student's t-test for normally distributed variables
and the Wilcoxon test for variables not normally dis-
tributed [Lp(a)]. Whenever necessary, the data were
transformed to natural logarithms before analysis. The
Pearson correlation coefficient (r) was used as a meas-
urement of correlation. Association of lipid and other
parameters with atherosclerotic occlusive disease of
the lower extremities was examined in multiple
regression analysis.
Results
Demographic data of patients and controls are shown
in Table 1. Age and BMI did not differ between
patients and controls while the prevalence of diabetes
as well as of hypertension was very high in the group
of patients compared to that of the controls.
Table 2. Mean value xÅ and standard deviation (SD) of the examined variables in patients and controls;
p-value for corresponding comparisons.
Patients
(n 52)
xÅ  SD
Control
(n 75)
xÅ  SD
p-value
Total cholesterol (mmol/l) 5.5 1.8 5.5 1.1 NS
Triglycerides (mmol/l) 1.6 1.3 1.3 0.6 NS
HDL-cholesterol (mmol/l) 0.9 0.3 1.3 0.3 0.000001
Non HDL-cholesterol (mmol/l) 4.5 1.6 4.2 1.1 NS
ApoAI (g/l) 1 0.4 1.3 0.2 0.000001
ApoB (g/l) 1.2 0.4 1.2 0.3 NS
Lp(a) (mg/l) median (range) 200 (6.9±2780) 75 (7.5±1130) 0.000001y
ApoB : ApoAI ratio 1.3 0.4 0.9 0.3 0.000001
Total cholesterol : HDL-cholesterol ratio 6.11.8 4.6 1.4 0.000001
NSNon significant.After logarithmic transformation.
yWilcoxon test.
Table 3. Multiple linear regression analysis between patients and
controls (as dependent variable) of Lp(a), ApoAl, HDL-choles-
terol, diabetes and hypertension (as independent variables);
regression coefficients (b), standard error of b (SEb) with corre-
sponding p-value.
Independent variable b SEb t p-value
A Lp(a) 0.002 0.0007 2.91 0.004
ApoAI ÿ0.001 0.001 ÿ1.33 0.18
HDL-cholesterol ÿ0.003 0.003 ÿ0.99 0.32
Diabetes 0.344 0.107 3.22 0.001
Hypertension 0.394 0.094 4.19 0.00005
B Lp(a) 0.002 0.0007 2.86 0.004
ApoAI ÿ0.002 0.001 ÿ2.02 0.04
Diabetes 0.366 0.104 3.51 0.0006
Hypertension 0.397 0.094 4.22 0.00004
When HDL-cholesterol was excluded from the model (see Results).
Table 4. Mean value (xÅ) and standard deviation (SD), of the ex-
amined variables in patients with atherosclerotic occlusive dis-
ease of the lower extremities with or without diabetes; p-value for
corresponding comparisons.
xÅ  SD p-value
Non-diabetics
(n 24)
Diabetics
(n 28)
Glucose blood levels
(mmol/l)
4.9 0.8 9.2 2.9
Total cholesterol (mmol/l) 6.11.6 4.9 1.8 0.01
Triglycerides (mmol/l) 1.5 0.9 1.7 1.6 NS
HDL-cholesterol (mmol/l) 1.1 0.3 0.8 0.3 0.00005
Non HDL-cholesterol
(mmol/l)
5.0 1.5 4.11.7 NS
ApoAI (g/l) 1.2 0.4 0.8 0.3 0.0003
ApoB (g/l) 1.3 0.4 1.2 0.5 NS
Lp(a) (mg/l) Median
(range)
182
(6.9±2780)
270
(70±1770)
NSy
ApoB : ApoAI ratio 1.1 0.3 1.5 0.4 0.0004
Total cholesterol : HDL-
cholesterol ratio
5.6 1.5 6.6 2 NS
ApoB : non HDL-cholesterol
ratio
0.7 0.1 0.8 0.2 0.007
NSNon significant.After logarithmic transformation.
yWilcoxon test.
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shown in Table 2. There was a significant decrease
in ApoAI as well as in HDL cholesterol serum levels
in patients as compared to those in the controls
(p 0.000001 for both). The distribution of Apo(a) or
Lp(a) protein levels among patients or controls was
highly skewed and a significant increase of Lp(a)
serum levels in patients as compared to those in
the controls (p 0.000001) was observed (Table 2). A
significant correlation was found between ApoAI and
HDL-cholesterol in the patients (r 0.79, p 0.000001)
but not in controls (r 0.15, p 0.2).
Diabetes, hypertension, ApoAI, HDL-cholesterol
and Lp(a) were entered into the multiple regression
analysis which revealed high Lp(a) levels (p 0.004),
hypertension and diabetes to be significantly asso-
ciated with atherosclerotic occlusive disease (Table
3). Due to the significant correlation between ApoAI
and HDL-cholesterol levels when HDL-cholesterol
was excluded from the model of regression analysis
(Table 3(b)) the disease was also correlated with the
low ApoAI levels (p 0.04). On the contrary, when
alternatively ApoAI was excluded from the model,
there was not any correlation between the disease
and low HDL-cholesterol levels (p 0.08).
Diabetic patients had a significantly lower ApoAI
(p 0.0003), HDL-cholesterol (p 0.00005) and total
cholesterol (p 0.01) serum levels as compared to
non-diabetic patients (Table 4).
Multiple regression analysis with diabetes as
dependent variable, and ApoAI and total cholesterol
as independent variables, confirmed that ApoAI,
but not total cholesterol, was associated with the
presence of diabetes (p 0.009). If alternatively
ApoAI was exchanged for HDL-cholesterol in the
above model, low HDL-cholesterol levels were also
significantly associated with the presence of diabetes
(p 0.002).Eur J Vasc Endovasc Surg Vol 24, August 2002
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Investigations into the plasma lipid profile, associated
with extracoronary atherosclerosis were in part influ-
enced by ischemic heart disease studies; however
findings indicated that peripheral atherosclerosis
shows some peculiar characteristics with respect to
coronary atherosclerosis.
Peripheral atherosclerosis has been associated with
an increase in triglycerides and with a reduction in
HDL-cholesterol serum levels.3,5 This link, however,
has not been a universal finding.6,8 These modifica-
tions in triglycerides and HDL-cholesterol serum
levels may be related to the direct metabolic effects
of smoking and diabetes, which frequently coexist
with arterial occlusive disease.8 Data concerning the
association of total or LDL-cholesterol serum levels
with peripheral vascular disease (PVD) are also
contradictory.2,3,9 This could be due in part to the
low HDL-cholesterol levels which influence the
total cholesterol levels1 or to the elevation in VLDL-
cholesterol.18 We found no difference in triglycerides
nor in total cholesterol serum levels between patients
and controls confirming our previous study.4 Only
a high significant decrease in HDL-cholesterol
resulting in an elevation of total cholesterol to HDL-
cholesterol ratio was observed in patients compared to
the controls (Table 2).
Several reports indicate that the lipid variable with
the strongest association of coronary artery disease
was the ratio of ApoB/ApoAI,19,20 but only a few
recent studies with contradictory results report the
correlation of apolipoproteins with aortofemoral
atherosclerosis.9,21,22 We observed a significant in-
crease of ApoB to ApoAI ratio in patients as compared
to that in controls as a result of the very low ApoAI
levels in patients (Table 2). Multiple regression analy-
sis suggested a negative relationship between ApoAI
levels and the disease. Apolipoprotein AI influences
the cholesterol composition and particle size of
HDL.23 In this sense the positive correlation observed
between ApoAI and HDL-cholesterol in the group of
patients of this study indicates that the decrease of
HDL-cholesterol in patients (Table 2) was due to
ApoAI and not to other factors such as cholesteryl
ester transfer protein, CETP.24 Recent data give
support to ApoAI involvement in the reverse choles-
terol transport, anti-inflammatory and antithrombotic
mechanisms, all of which are antiatherogenic.25
Few studies have relatively considered the relation-
ship between lipid levels and PVD in diabetic subjects
as a subgroup and, while increased total cholesterol,
decreased HDL-cholesterol and increased triglyceride
levels have been reported, here too the results haveEur J Vasc Endovasc Surg Vol 24, August 2002been inconsistent.3,18,26 We found a significant
decrease of ApoAI, HDL-cholesterol and total choles-
terol in diabetic patients compared to the non-diabetic
patients (Table 4). Multiple regression analysis
revealed the negative association between ApoAI
levels and diabetes. Therefore we could say that the
observed decrease of HDL-cholesterol in diabetic
patients compared to the non-diabetic patients was
due to the low ApoAI levels in diabetics leading, at
the same time, to the reduction of total cholesterol
(Table 4). The ratio of ApoB/non HDL-cholesterol
was significantly higher in diabetic patients (Table 4)
indicating the higher number of ApoB-lipoprotein
particles (LDL and VLDL remnants). This finding
according to Abate et al. reflects a shift in ApoB-
lipoprotein size to smaller particles which confer an
increased atherogenic potential.16 Small LDL-particles
have now been well documented in subjects with
diabetes.3
Lp(a) promotes cholesterol accumulation in the
arterial wall and is antifibrinolytic.27 In the study
population, the distribution of Lp(a) is skewed con-
sistently with other reports concerning the distribu-
tion of Lp(a) levels in the Greek population.28 Recent
data have suggested a strong relationship between
Lp(a) and peripheral vascular occlusive disease.4,7,9
We found a significant increase in Lp(a) serum levels
in both diabetic and non diabetic patients compared to
the controls. The relationship of Lp(a) and diabetes is
not clear. In agreement with Cheng et al.9 and in dis-
agreement with others,29 we did not find any signifi-
cant correlation of Lp(a) levels with diabetes or fasting
blood glucose concentration. Furthermore, regression
analysis revealed Lp(a) as an independent risk factor
for the disease (Table 3(a)). Thus an unfavourable
serum lipid profile was found in the patients of the
present study, caused by low levels of ApoAI (leading
to the reduced HDL) and high levels of Lp(a). At this
point, it would be worthwhile saying that in the group
of patients studied the prevalence of two traditional
risk factors for PVD is high: diabetes (54%) and hyper-
tension (46%) (Table 1). In the presence of dyslipid-
aemia these risk factors may further potentiate
atherogenesis. The history of CVD in a percentage
of 42% in patients could indicate the risk of develop-
ing atherosclerosis. On the other hand diabetes
which could influence the lipidaemic profile and
regression analysis revealed diabetes as well as
hypertension as confounding factors (Table 3). How-
ever there is evidence that even in diabetes develop-
ing atherosclerosis is associated with an unfavourable
serum lipid profile.8,26
There is no doubt that the occurrence of peripheral
vascular occlusive disease depends on many factors
Accepted 18 April 2002
Apolipoprotein AI Levels and PVD 165which come into play; however, among them low
levels of ApoAI (HDL) and high levels of Lp(a) may
be involved in the pathophysiology of the disease.
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